Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Early Success For Kalydeco Is Just The Beginning For Vertex’s CF Drug

Executive Summary

Kalydeco is expected to be a game-changer in cystic fibrosis, but its current label is applicable to only 4% of the patient population. Vertex, however, has an ongoing plan to expand Kalydeco’s label as both a monotherapy and in combination with other experimental CF agents.

You may also be interested in...

Vertex's Cystic Fibrosis Drug Kalydeco Given Green Light By EU's Scientific Advisory Panel

Vertex's cystic fibrosis product Kalydeco is one of five new molecular entities given a positive opinion by Europe's Committee for Medicinal Products for Human Use on May 25, which also included Almirall's novel COPD therapy aclidinium and Novo Nordisk's recombinant Factor XIII.

Vertex’s CF Therapy Combination Trial Yields Promising Lung-Function Data

Interim data from a Phase II study investigating Kalydeco with VX-809 showed statistically significant FEV-1 improvement across dosing groups; the company hopes to start a pivotal Phase III program for the combo in late 2012 or early 2013.

Innovative Drug Development: Kalydeco Provides A Paradigm, FDA’s Spielberg Says

The deputy commissioner detailed the steps involved in getting Vertex’s cystic fibrosis drug rapidly through the approval process and noted that FDA is working on innovative study designs and assessing how to better use diagnostics.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts